Italia markets closed

PFE Mar 2025 34.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,6200-0,0500 (-7,46%)
In data: 02:45PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,6700
Aperto0,5700
Denaro0,5700
Domanda0,7400
Prezzo d'esercizio34,00
Scadenza2025-03-21
Min-Max giorno0,4700 - 0,6200
Contratto - Min-MaxN/D
Volume125
Open Interest11,16k
  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g